Carroll Financial Associates’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | $614K | Buy |
4,009
+390
| +11% | +$60.4K | 0.03% | 233 |
|
|
2021
Q3 | $585K | Sell |
3,619
-450
| -11% | -$75.7K | 0.03% | 239 |
|
|
2021
Q2 | $665K | Buy |
4,069
+129
| +3% | +$19.9K | 0.04% | 224 |
|
|
2021
Q1 | $593K | Buy |
3,940
+139
| +4% | +$22.1K | 0.04% | 231 |
|
|
2020
Q4 | $575K | Buy |
3,801
+67
| +2% | +$9.57K | 0.04% | 223 |
|
|
2020
Q3 | $505K | Sell |
3,734
-4,136
| -53% | -$561K | 0.04% | 218 |
|
|
2020
Q2 | $1.07M | Buy |
7,870
+3,926
| +100% | +$500K | 0.09% | 138 |
|
|
2020
Q1 | $424K | Sell |
3,944
-216
| -5% | -$24.9K | 0.04% | 214 |
|
|
2019
Q4 | $501K | Sell |
4,160
-250
| -6% | -$27.9K | 0.04% | 214 |
|
|
2019
Q3 | $438K | Sell |
4,410
-504
| -10% | -$52.8K | 0.04% | 233 |
|
|
2019
Q2 | $536K | Sell |
4,914
-1,762
| -26% | -$187K | 0.05% | 204 |
|
|
2019
Q1 | $746K | Buy |
6,676
+2,093
| +46% | +$230K | 0.07% | 148 |
|
|
2018
Q4 | $485K | Sell |
4,583
-1,529
| -25% | -$162K | 0.05% | 158 |
|
|
2018
Q3 | $745K | Hold |
6,112
| – | – | 0.08% | 141 |
|
|
2018
Q2 | $671K | Buy |
6,112
+181
| +3% | +$19.4K | 0.07% | 145 |
|
|
2018
Q1 | $633K | Sell |
5,931
-375
| -6% | -$41.6K | 0.07% | 142 |
|
|
2017
Q4 | $673K | Sell |
6,306
-255
| -4% | -$27.3K | 0.07% | 137 |
|
|
2017
Q3 | $745K | Buy |
6,561
+60
| +0.9% | +$6.41K | 0.08% | 122 |
|
|
2017
Q2 | $671K | Buy |
6,501
+579
| +10% | +$57K | 0.08% | 131 |
|
|
2017
Q1 | $578K | Buy |
5,922
+27
| +0.5% | +$2.58K | 0.07% | 137 |
|
|
2016
Q4 | $521K | Sell |
5,895
-1,917
| -25% | -$174K | 0.07% | 141 |
|
|
2016
Q3 | $753K | Buy |
7,812
+462
| +6% | +$44K | 0.11% | 112 |
|
|
2016
Q2 | $630K | Sell |
7,350
-276
| -4% | -$24.8K | 0.11% | 120 |
|
|
2016
Q1 | $662K | Sell |
7,626
-126
| -2% | -$11.3K | 0.12% | 106 |
|
|
2015
Q4 | $874K | Buy |
7,752
+108
| +1% | +$11.7K | 0.18% | 88 |
|
|
2015
Q3 | $775K | Sell |
7,644
-24
| -0.3% | -$2.88K | 0.17% | 95 |
|
|
2015
Q2 | $943K | Buy |
7,668
+2,238
| +41% | +$268K | 0.21% | 76 |
|
|
2015
Q1 | $622K | Buy |
5,430
+2,556
| +89% | +$282K | 0.27% | 69 |
|
|
2014
Q4 | $299K | Buy |
2,874
+6
| +0.2% | +$583 | 0.19% | 93 |
|
|
2014
Q3 | $283K | Hold |
2,868
| – | – | 0.09% | 126 |
|
|
2014
Q2 | $246K | Buy |
2,868
+249
| +10% | +$19.6K | 0.07% | 151 |
|
|
2014
Q1 | $206K | Buy |
2,619
+576
| +28% | +$48K | 0.07% | 147 |
|
|
2013
Q4 | $154K | Hold |
2,043
| – | – | 0.05% | 161 |
|
|
2013
Q3 | $142K | Sell |
2,043
-15
| -0.7% | -$983 | 0.05% | 165 |
|
|
2013
Q2 | $119K | Buy |
+2,058
| New | +$119K | 0.06% | 149 |
|
Other funds holding IBB
CB
Carroll Financial Associates's IBB Position: Q4 2021 in Review
Carroll Financial Associates increased its iShares Biotechnology ETF (IBB) stake by 11% in Q4 2021, buying an estimated $60.4K and bringing the position to 4,009 shares worth $614K. The position accounts for 0.03% of the portfolio, ranked #233.
Carroll Financial Associates first reported a position in IBB in Q2 2013 and has held it in 35 quarters since. The position peaked at $1.07M in Q2 2020. 963 funds tracked by Wall St. Rank hold IBB as of Q4 2021.
- Carroll Financial Associates held 4,009 shares of iShares Biotechnology ETF worth $614K as of Q4 2021.
- Carroll Financial Associates bought 390 iShares Biotechnology ETF shares in Q4 2021, an estimated $60.4K.
- iShares Biotechnology ETF made up 0.03% of Carroll Financial Associates's portfolio in Q4 2021, its #233 holding.
- Carroll Financial Associates first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 35 quarters since.
- Carroll Financial Associates's iShares Biotechnology ETF position peaked at $1.07M in Q2 2020.
- 963 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2021.
Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.